Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose‐ranging study
Botticelli investigators, the writing … - … of Thrombosis and …, 2008 - Wiley Online Library
Background: Apixaban, an oral potent reversible direct inhibitor of activated factor X, has
shown promise in the prevention of venous thromboembolism following major orthopedic …
shown promise in the prevention of venous thromboembolism following major orthopedic …
Apixaban for extended treatment of venous thromboembolism
Background Apixaban, an oral factor Xa inhibitor that can be administered in a simple, fixed-
dose regimen, may be an option for the extended treatment of venous thromboembolism …
dose regimen, may be an option for the extended treatment of venous thromboembolism …
Oral apixaban for the treatment of acute venous thromboembolism
Background Apixaban, an oral factor Xa inhibitor administered in fixed doses, may simplify
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …
the treatment of venous thromboembolism. Methods In this randomized, double-blind study …
The role of factor Xa inhibitors in venous thromboembolism treatment
KP Cabral, JE Ansell - Vascular Health and Risk Management, 2015 - Taylor & Francis
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism,
both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban …
both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban …
Apixaban for the treatment of Japanese subjects with acute venous thromboembolism (AMPLIFY-J Study)
M Nakamura, M Nishikawa, I Komuro, I Kitajima… - Circulation …, 2015 - jstage.jst.go.jp
Background: Anticoagulation is recommended as standard of care for venous
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …
thromboembolism (VTE)(pulmonary embolism [PE]/deep vein thrombosis [DVT]), for which …
Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose
TA Leil, Y Feng, L Zhang, A Paccaly… - CliniCal …, 2010 - Wiley Online Library
A model‐based approach was used to integrate data from a phase II study in order to
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
provide a quantitative rationale for selecting the apixaban dosage regimen for a phase III …
A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban
C Frost, Y Song, YC Barrett, J Wang… - Clinical …, 2014 - Taylor & Francis
Background Currently, there are no direct comparisons of apixaban and rivaroxaban, two
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …
new oral direct factor Xa inhibitors approved for management of thromboembolic disorders …
Apixaban, an oral direct Factor Xa inhibitor: awaiting the verdict
J Carreiro, J Ansell - Expert Opinion on Investigational Drugs, 2008 - Taylor & Francis
For the last half-century, despite its many limitations warfarin has been the mainstay of
treatment for patients with venous and arterial thromboembolic disease. During the past …
treatment for patients with venous and arterial thromboembolic disease. During the past …
[HTML][HTML] Apixaban: a clinical pharmacokinetic and pharmacodynamic review
W Byon, S Garonzik, RA Boyd, CE Frost - Clinical pharmacokinetics, 2019 - Springer
Apixaban is an oral, direct factor Xa inhibitor that inhibits both free and clot-bound factor Xa,
and has been approved for clinical use in several thromboembolic disorders, including …
and has been approved for clinical use in several thromboembolic disorders, including …
A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects
YC Barrett, J Wang, Y Song, J Pursley… - Thrombosis and …, 2012 - thieme-connect.com
Following major orthopaedic surgery, guidelines usually recommend continued
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …
thromboprophylaxis after hospitalisation. The availability of an effective oral anticoagulant …